JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% ...

CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for ...

Mirum Pharmaceuticals, Inc. today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® ...

Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

Harmony Biosciences (HRMY) announced the appointment of Adam Zaeske as executive VP and chief commercial officer, effective March 31. The ...

Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 123.6% during the fourth quarter, Holdings Channel reports. The institutional ...

Fintel reports that on March 21, 2025, Benchmark initiated coverage of Kamada (NasdaqGS:KMDA) with a Buy recommendation.

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Due to hemophilia A patients switching to newer treatments, Takeda Pharmaceuticals is discontinuing both Hemofil M and ...

One company to watch right now is Takeda Pharmaceutical Co. (TAK). TAK is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. We should also highlight that TAK has a P/B ratio of 0.99.

Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company ...

Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire ...